Efficacy of Controlled-Release Paroxetine in the Treatment of Late-Life Depression

帕罗西汀 安慰剂 临床终点 萧条(经济学) 内科学 重性抑郁障碍 晚年抑郁症 医学 随机对照试验 心理学 精神科 抗抑郁药 海马结构 经济 病理 替代医学 宏观经济学 扁桃形结构 海马体
作者
Mark Hyman Rapaport,Lon S. Schneider,David L. Dunner,J. Davies,Cornelius D. Pitts
出处
期刊:The Journal of Clinical Psychiatry [Physicians Postgraduate Press, Inc.]
卷期号:64 (9): 1065-1074 被引量:97
标识
DOI:10.4088/jcp.v64n0912
摘要

Depression is the second most common neuropsychiatric disorder in older Americans, with significant clinical and public health costs. Despite advances in treatment, late-life depression remains a clinical challenge. Although the selective serotonin reuptake inhibitors (SSRIs) are the most common pharmacologic intervention for late-life depression, few placebo-controlled trials have assessed the efficacy of SSRIs for this condition.In this 12-week, multicenter, placebo-controlled, flexible-dose, double-blind, randomized trial, 319 elderly patients (mean age = 70 years) were treated with controlled-release paroxetine (paroxetine CR) up to 50 mg/day (N = 104), immediate-release paroxetine (paroxetine IR) up to 40 mg/day (N = 106), or placebo (N = 109). Patients met DSM-IV criteria for major depressive disorder and had a total score of 18 or more on the 17-item Hamilton Rating Scale for Depression (HAM-D). The primary efficacy measure was change from baseline to endpoint in HAM-D total score.The primary efficacy analysis showed an adjusted difference between change from baseline in HAM-D score for paroxetine CR and placebo of -2.6 (95% confidence interval [CI] = -4.47 to -0.73, p = .007) at the week 12 last-observation-carried-forward (LOCF) endpoint. The adjusted difference between paroxetine IR and placebo was -2.8 (95% CI = -4.65 to -0.99, p = .003) at week 12. Paroxetine CR and IR were more effective than placebo, with mean +/- SD endpoint HAM-D total scores of 10.0 +/- 7.41 and 10.0 +/- 7.10, respectively, for the active treatments compared with 12.6 +/- 7.34 for placebo. Response, defined as a score of 1 or 2 on the Clinical Global Impressions-global improvement scale, was achieved by 72% of paroxetine CR patients (LOCF; p < .002 vs. placebo), 65% of paroxetine IR patients (p = .06 vs. placebo), and 52% of placebo patients. Remission, defined as a HAM-D total score < or = 7, was achieved by 43% of paroxetine CR patients (LOCF; p = .009 vs. placebo), 44% of paroxetine IR patients (p = .01 vs. placebo), and 26% of placebo patients. In a post hoc analysis, mean HAM-D improvement for paroxetine CR and paroxetine IR was greater than for placebo in both chronically depressed patients (duration > 2 years) and those with short-term (< or = 2 years) depression. Dropout rates due to adverse events were 12.5% for paroxetine CR, 16.0% for paroxetine IR, and 8.3% for placebo.Paroxetine CR and paroxetine IR are effective and well tolerated treatments for major depressive disorder in elderly patients, including those with chronic depression.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CodeCraft的应助被肚肚采纳,获得10
1秒前
1秒前
林小鱼完成签到,获得积分10
1秒前
1秒前
阑珊完成签到,获得积分10
1秒前
2秒前
osh发布了新的文献求助30
2秒前
策力格尔完成签到,获得积分10
2秒前
向向卉发布了新的文献求助10
2秒前
XING发布了新的文献求助10
2秒前
3秒前
shouz发布了新的文献求助10
3秒前
3秒前
molihuakai的应助被nacoo采纳,获得10
3秒前
小爽完成签到,获得积分10
3秒前
lzd发布了新的文献求助10
4秒前
4秒前
上下发布了新的文献求助10
4秒前
5秒前
Sunshine完成签到,获得积分10
6秒前
6秒前
小爽发布了新的文献求助10
6秒前
由十三完成签到,获得积分10
6秒前
zhiren发布了新的文献求助10
7秒前
7秒前
tt完成签到,获得积分10
7秒前
王海祥发布了新的文献求助10
7秒前
7秒前
李哈哈完成签到,获得积分20
8秒前
大丑橘粑粑柑公主完成签到,获得积分10
8秒前
脑斧儿完成签到,获得积分10
9秒前
852的应助被chiweiyoung采纳,获得10
9秒前
见路不走发布了新的文献求助10
9秒前
xiang完成签到,获得积分10
10秒前
11秒前
风格发布了新的文献求助10
11秒前
溜达完成签到,获得积分10
12秒前
XING完成签到,获得积分10
13秒前
yhs发布了新的文献求助10
13秒前
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Monte Cassino in the Middle Ages Volume I 310
JUSTIFICATION OF SMALL-SCALE MODELS: AN INDUSTRY PERSPECTIVE 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8156821
求助须知:如何正确求助?哪些是违规求助? 9553001
关于积分的说明 21712377
捐赠科研通 7745993
什么是DOI,文献DOI怎么找? 3426679
关于科研通互助平台的介绍 2551456
邀请新用户注册赠送积分活动 2470530